Better access to patient information would enable researchers to answer new questions with existing data, validate findings, and combine the power from individual studies.
Difficulties in obtaining patient data on the effects of heart failure drugs from previously published clinical trials are making it impossible to assess the outcomes of these drugs on patients, according to an article published yesterday in the BMJ.
These problems accessing data from clinical trials means that only part of the evidence base is available, and this may lead to erroneous clinical decisions, writes lead author Robert Fleetcroft, MD, clinical lecturer in general practice at the Norwich Medical School at the University of East Anglia, UK.
The research team carried out a systematic review of the effectiveness of heart failure drugs for patients with minor symptoms. They found 30 studies that looked at the effect of these drugs -- beta blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers -- on heart failure. However, none of the studies included enough data to assess outcomes for patients with the varying degrees of minor symptoms required.
Fleetcroft and collegues said they were surprised at the difficulties they faced, even though most studies were published between the 1990s and 2010. Four had been published since 2010.
"We need central national repositories for trial data based in the country of the trial sponsor," they noted, adding that mechanisms of data sharing must be developed and coordinated actions from funders, journals, ethics, committees, and national guideline developing bodies are vital.
Better access to patient information would enable researchers to answer new questions with existing data, validate findings, and combine the power from individual studies, and it may also prevent selective reporting and research fraud, according to Fleetcroft et al.
Furthermore, bodies involved in national guidelines have a role to play, and it is unacceptable for these groups to make decisions about new drugs based on clinical effectiveness data that are not in the public domain, they stated. Such transparency is essential to bolster trust in the process of evaluation of new treatments.
Finally, they recommend that research ethics and funding committees should make future access to data a mandatory requirement, and funders should cover the costs of archiving data and journals should require evidence of archived data.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.